The trial is entitled “TASKi: Treatment of Arthritis With Syk Kinase Inhibition” and is currently recruiting.
TASKi is composed of two studies:
- A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Dose Study of R935788 in Patients with Rheumatoid Arthritis who have failed at least one biologic.
- A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Dose Study of Two Doses of R935788 in Rheumatoid Arthritis Patients Failing to respond to Methotrexate.
To view testing sites across the U.S., visit our Clinical Trials listing page.
Criteria for admittance and further information can be found by visiting:
For contact info, visit:
For additional information, visit: